Beyond Air Reports 34% Revenue Growth and Expands Global Market Access with CE Mark for LungFit PH
核心洞察
Beyond Air (搜索) achieves significant commercial milestone with quarterly revenues exceeding $1 million, marking a 34% increase from the previous quarter.
Company secures CE Mark certification for LungFit PH (搜索) in Europe and regulatory authorization in Australia, paving way for international market expansion.
Strategic partnerships established in Middle East and Asia-Pacific regions, with commercial shipments expected to commence in 2025.
Beyond Air (搜索) has reported substantial commercial progress in its fiscal third quarter ended December 31, 2024, with revenues surpassing $1.1 million, representing a 34% increase from the previous quarter. The company's flagship product, LungFit PH (搜索), continues to gain traction in the U.S. healthcare market.
Global Market Expansion
The company achieved a significant milestone with the receipt of CE Mark certification for LungFit PH (搜索), enabling market access across the European Union and other regions recognizing this certification. The approved indications include:
- Treatment of infants >34 weeks gestation with hypoxic respiratory failure associated with pulmonary hypertension
- Management of peri- and post-operative pulmonary hypertension in patients aged 0-17 years undergoing heart surgery
This certification triggered a $1 million milestone payment from Getz Healthcare (搜索), Beyond Air (搜索)'s Asia-Pacific distribution partner, and establishes the framework for double-digit royalty payments based on future sales.
Commercial Progress and Market Penetration
Steve Lisi, Chairman and CEO of Beyond Air (搜索), highlighted the company's commercial momentum: "Our commercial team continues to make significant progress as we expand the number of U.S. hospitals utilizing LungFit PH (搜索). We expect to continue generating double-digit sequential quarterly revenue growth for the foreseeable future."
The quarter saw six new hospital implementations in the U.S., demonstrating growing market acceptance. The company has also secured strategic partnerships with two distributors in the Middle East, with initial shipments planned for the first half of 2025.
Pipeline Development and Clinical Programs
Beyond Air (搜索) continues to advance its product pipeline:
- A cardiac surgery PMA supplement review is ongoing with the FDA
- A transport-ready PMA supplement submission for LungFit PH is anticipated in the coming months
- Beyond Cancer, the company's oncology program, is progressing with Phase 1 trials evaluating ultra-high concentration Nitric Oxide therapy for solid tumors
Financial Position
The company reported:
- Cash, cash equivalents, and marketable securities of $10.9 million
- Total debt of $11.8 million with repayment beginning October 2026
- Implementation of cash conservation strategies alongside anticipated revenue growth
- Projected cash runway extending well into calendar 2026
The company's focus on operational efficiency is reflected in reduced research and development expenses, which decreased to $3.0 million from $6.8 million in the comparable quarter of the previous year. Similarly, selling, general, and administrative expenses decreased by $2.1 million to $7.7 million.